|
2020 Journal Article Effectiveness and Safety of Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Diabetes MellitusLip, Gregory Y.H., Keshishian, Allison V., Kang, Amiee L., Li, Xiaoyan, Dhamane, Amol D., Luo, Xuemei, Balachander, Neeraja, Rosenblatt, Lisa, Mardekian, Jack, Nadkarni, Anagha, Pan, Xianying, Di Fusco, Manuela, Garcia Reeves, Alessandra B., Yuce, Huseyin and Deitelzweig, Steven B. (2020). Effectiveness and Safety of Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Diabetes Mellitus. Mayo Clinic Proceedings, 95 (5), 929-943. doi: 10.1016/j.mayocp.2019.05.032 |
|
2020 Journal Article Comparison of readmissions among hospitalized nonvalvular atrial fibrillation patients treated with oral anticoagulants in the United StatesDeitelzweig, Steven, Baker, Christine L., Dhamane, Amol D., Mardekian, Jack, Dina, Oluwaseyi, Rosenblatt, Lisa, Russ, Cristina, Poretta, Tayla, Lingohr-Smith, Melissa and Lin, Jay (2020). Comparison of readmissions among hospitalized nonvalvular atrial fibrillation patients treated with oral anticoagulants in the United States. Journal of Drug Assessment, 9 (1), 87-96. doi: 10.1080/21556660.2020.1750418 |
|
2020 Journal Article Utilization of anticoagulants and predictors of treatment among hospitalized patients with atrial fibrillation in the USADeitelzweig, Steven, Dhamane, Amol D., Di Fusco, Manuela, Russ, Cristina, Rosenblatt, Lisa, Lingohr-Smith, Melissa and Lin, Jay (2020). Utilization of anticoagulants and predictors of treatment among hospitalized patients with atrial fibrillation in the USA. Journal of Medical Economics, 23 (12), 1-12. doi: 10.1080/13696998.2020.1832099 |
|
2020 Journal Article Comparison of inpatient admission rates of patients treated with apixaban vs. warfarin for venous thromboembolism in the emergency departmentDeitelzweig, Steven, Hlavacek, Patrick, Mardekian, Jack, Rosenblatt, Lisa, Russ, Cristina, Tuell, Kenneth, Lingohr-Smith, Melissa, Lin, Jay and Guo, Jennifer D. (2020). Comparison of inpatient admission rates of patients treated with apixaban vs. warfarin for venous thromboembolism in the emergency department. Hospital Practice, 48 (1), 41-48. doi: 10.1080/21548331.2020.1718925 |
|
2020 Journal Article Major bleed costs of atrial fibrillation patients treated with factor Xa inhibitor anticoagulantsFermann, Gregory J., Lovelace, Belinda, Christoph, Mary J., Lingohr-Smith, Melissa, Lin, Jay and Deitelzweig, Steven B. (2020). Major bleed costs of atrial fibrillation patients treated with factor Xa inhibitor anticoagulants. Journal of Medical Economics, 23 (12), 1409-1417. doi: 10.1080/13696998.2020.1837502 |
|
2019 Journal Article Budget impact analysis of betrixaban for venous thromboembolism prophylaxis in nonsurgical patients with acute medical illness in the United KingdomGuy, Holly, Laskier, Vicki, Fisher, Mark, Bucior, Iwona, Deitelzweig, Steven and Cohen, Alexander T. (2019). Budget impact analysis of betrixaban for venous thromboembolism prophylaxis in nonsurgical patients with acute medical illness in the United Kingdom. Expert Review of Pharmacoeconomics and Outcomes Research, 20 (3), 1-9. doi: 10.1080/14737167.2019.1629905 |
|
2019 Journal Article Cost-effectiveness of betrixaban compared with enoxaparin for venous thromboembolism prophylaxis in nonsurgical patients with acute medical illness in the United StatesGuy, Holly, Laskier, Vicki, Fisher, Mark, Neuman, W. Richey, Bucior, Iwona, Deitelzweig, Steven and Cohen, Alexander T. (2019). Cost-effectiveness of betrixaban compared with enoxaparin for venous thromboembolism prophylaxis in nonsurgical patients with acute medical illness in the United States. Pharmacoeconomics, 37 (5), 701-714. doi: 10.1007/s40273-018-0757-8 |
|
2019 Journal Article Frequency of hospital readmissions for venous thromboembolism and associated hospital costs and length of stay among acute medically ill patients in the USAmin, Alpesh, Deitelzweig, Steven, Bucior, Iwona, Lin, Jay, Lingohr-Smith, Melissa, Menges, Brandy and Neuman, W. Richey (2019). Frequency of hospital readmissions for venous thromboembolism and associated hospital costs and length of stay among acute medically ill patients in the US. Journal of Medical Economics, 22 (11), 1-7. doi: 10.1080/13696998.2019.1618862 |
|
2019 Journal Article Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation PatientsDeitelzweig, Steven, Keshishian, Allison, Li, Xiaoyan, Kang, Amiee, Dhamane, Amol D., Luo, Xuemei, Balachander, Neeraja, Rosenblatt, Lisa, Mardekian, Jack, Pan, Xianying, Nadkarni, Anagha, Di Fusco, Manuela, Garcia Reeves, Alessandra B., Yuce, Huseyin and Lip, Gregory Y. H. (2019). Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients. Journal of the American Geriatrics Society, 67 (8) jgs.15956, 1662-1671. doi: 10.1111/jgs.15956 |
|
2019 Journal Article Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with -vitamin K antagonists in patients with non-valvular atrial fibrillation: a systematic literature reviewDeitelzweig, Steve and Lip, Gregory Y. H. (2019). Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with -vitamin K antagonists in patients with non-valvular atrial fibrillation: a systematic literature review. Expert Review of Pharmacoeconomics and Outcomes Research, 19 (3), 1-2. doi: 10.1080/14737167.2019.1592834 |
|
2018 Journal Article Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients The ARISTOPHANES StudyLip, Gregory Y. H., Keshishian, Allison, Li, Xiaoyan, Hamilton, Melissa, Masseria, Cristina, Gupta, Kiran, Luo, Xuemei, Mardekian, Jack, Friend, Keith, Nadkarni, Anagha, Pan, Xianying, Baser, Onur and Deitelzweig, Steven (2018). Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients The ARISTOPHANES Study. Stroke, 49 (12), 2933-2944. doi: 10.1161/STROKEAHA.118.020232 |
|
2018 Journal Article Hospital Resource Utilization and Costs Associated With Warfarin Versus Apixaban Treatment Among Patients Hospitalized for Venous Thromboembolism in the United StatesDeitelzweig, Steven, Guo, Jennifer D., Hlavacek, Patrick, Lin, Jay, Wygant, Gail, Rosenblatt, Lisa, Gupta, Anu, Pan, Xianying, Mardekian, Jack, Lingohr-Smith, Melissa, Menges, Brandy, Marshall, Alexander and Nadkarni, Anagha (2018). Hospital Resource Utilization and Costs Associated With Warfarin Versus Apixaban Treatment Among Patients Hospitalized for Venous Thromboembolism in the United States. Clinical and Applied Thrombosis-Hemostasis, 24 (9_suppl), 261S-268S. doi: 10.1177/1076029618800806 |
|
2018 Journal Article Impact of warfarin persistence on health-care utilization and costs among patients with atrial fibrillation managed in anticoagulation clinics in the United StatesDeitelzweig, Steven B., Evans, Michael, Trocio, Jeffrey, Gupta, Kiran, Lingohr-Smith, Melissa, Menges, Brandy and Lin, Jay (2018). Impact of warfarin persistence on health-care utilization and costs among patients with atrial fibrillation managed in anticoagulation clinics in the United States. Clinical and Applied Thrombosis-Hemostasis, 24 (2), 364-371. doi: 10.1177/1076029616685427 |
|
2018 Journal Article All-Cause, Stroke/Systemic Embolism-, and Major Bleeding-Related Health-Care Costs Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Oral AnticoagulantsDeitelzweig, Steve, Luo, Xuemei, Gupta, Kiran, Trocio, Jeffrey, Mardekian, Jack, Curtice, Tammy, Hlavacek, Patrick, Lingohr-Smith, Melissa, Menges, Brandy and Lin, Jay (2018). All-Cause, Stroke/Systemic Embolism-, and Major Bleeding-Related Health-Care Costs Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Oral Anticoagulants. Clinical and Applied Thrombosis/Hemostasis, 24 (4), 1076029617750269-611. doi: 10.1177/1076029617750269 |
|
2018 Journal Article Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approachLi, Xiaoyan, Keshishian, Allison, Hamilton, Melissa, Horblyuk, Ruslan, Gupta, Kiran, Luo, Xuemei, Mardekian, Jack, Friend, Keith, Nadkarni, Anagha, Pan, Xianying, Lip, Gregory Y. H. and Deitelzweig, Steve (2018). Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach. PLoS One, 13 (1) e0191722, e0191722. doi: 10.1371/journal.pone.0191722 |
|
2017 Journal Article Effect of Apixaban Versus Warfarin Use on Health Care Resource Utilization and Costs Among Elderly Patients with Nonvalvular Atrial FibrillationDeitelzweig, Steven, Luo, Xuemei, Gupta, Kiran, Trocio, Jeffrey, Mardekian, Jack, Curtice, Tammy, Lingohr-Smith, Melissa, Menges, Brandy and Lin, Jay (2017). Effect of Apixaban Versus Warfarin Use on Health Care Resource Utilization and Costs Among Elderly Patients with Nonvalvular Atrial Fibrillation. Journal of Managed Care & Specialty Pharmacy, 23 (11), 1191-1201. doi: 10.18553/jmcp.2017.17060 |
|
2017 Journal Article Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patientsDeitelzweig, Steven, Luo, Xuemei, Gupta, Kiran, Trocio, Jeffrey, Mardekian, Jack, Curtice, Tammy, Lingohr-Smith, Melissa, Menges, Brandy and Lin, Jay (2017). Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients. Current Medical Research and Opinion, 33 (10), 1745-1754. doi: 10.1080/03007995.2017.1334638 |
|
2017 Journal Article Incremental economic burden associated with major bleeding among atrial fibrillation patients treated with factor Xa inhibitorsDeitelzweig, Steven, Neuman, W. Richey, Lingohr-Smith, Melissa, Menges, Brandy and Lin, Jay (2017). Incremental economic burden associated with major bleeding among atrial fibrillation patients treated with factor Xa inhibitors. Journal of Medical Economics, 20 (12), 1217-1223. doi: 10.1080/13696998.2017.1362412 |
|
2017 Journal Article Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice: a propensity-matched analysis of 76,940 patientsLi, Xiaoyan, Deitelzweig, Steve, Keshishian, Allison, Hamilton, Melissa, Horblyuk, Ruslan, Gupta, Kiran, Luo, Xuemei, Mardekian, Jack, Friend, Keith, Nadkarni, Anagha, Pan, Xianying and Lip, Gregory Y. H. (2017). Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice: a propensity-matched analysis of 76,940 patients. Thrombosis and Haemostasis, 117 (6), 1072-1082. doi: 10.1160/TH17-01-0068 |
|
2017 Conference Publication Real World Evaluation of Major Bleeding Risk and Costs for All Causes and Bleeding-Related Health Services Among Elderly Patients with Nonvalvular Atrial Fibrillation Treated with Apixaban or WarfarinDeitelzweig, Steven, Luo, Xuemei, Gupta, Kiran, Trocio, Jeffrey, Mardekian, Jack, Cutice, Tammy, Lingohr-Smith, Melissa, Menges, Brandy and Lin, Jay (2017). Real World Evaluation of Major Bleeding Risk and Costs for All Causes and Bleeding-Related Health Services Among Elderly Patients with Nonvalvular Atrial Fibrillation Treated with Apixaban or Warfarin. 66th Annual Scientific Session and Expo of the American College of Cardiology (ACC), Washington DC, United States, Mar 17-19, 2017. San Diego, United States: Elsevier. |
